|
Volumn 42, Issue 11, 2001, Pages 2589-2595
|
Retinal dysfunction in cancer-associated retinopathy is improved by Ca2+ antagonist administration and dark adaptation
a
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CALCIUM ANTAGONIST;
NILVADIPINE;
PROTEIN ANTIBODY;
RECOVERIN;
RECOVERIN ANTIBODY;
RHODOPSIN;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
CANCER;
CONTROLLED STUDY;
DARK ADAPTATION;
DRUG EFFICACY;
ELECTRORETINOGRAPHY;
HISTOPATHOLOGY;
ILLUMINATION;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN PHOSPHORYLATION;
RAT;
RETINOPATHY;
ANIMALS;
ANTIBODIES;
ANTIGENS, NEOPLASM;
CALCIUM CHANNEL BLOCKERS;
CALCIUM-BINDING PROTEINS;
DARK ADAPTATION;
ELECTRORETINOGRAPHY;
EYE PROTEINS;
HIPPOCALCIN;
INJECTIONS;
INJECTIONS, INTRAPERITONEAL;
LIGHT;
LIPOPROTEINS;
NERVE TISSUE PROTEINS;
NIFEDIPINE;
PARANEOPLASTIC SYNDROMES;
PHOSPHORYLATION;
PHOTORECEPTORS, VERTEBRATE;
RATS;
RATS, INBRED BN;
RATS, INBRED LEW;
RECOVERIN;
RETINAL DISEASES;
RHODOPSIN;
VITREOUS BODY;
|
EID: 0034787950
PISSN: 01460404
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (30)
|
References (54)
|